MAOIs
MAOIs: Overview
Monoamine oxidase inhibitors (MAOIs) are a class of prescription medications best known for their role in treating certain mood disorders, particularly major depressive disorder that has not responded adequately to other therapies. They work by inhibiting the enzyme monoamine oxidase, which breaks down neurotransmitters such as serotonin, norepinephrine, and dopamine. By reducing this breakdown, MAOIs can increase the availability of these signaling chemicals in the brain. Historically, MAOIs were among the earliest antidepressants introduced into clinical practice and helped shape modern understanding of the neurochemical basis of depression.
Although MAOIs are effective for some patients, they are used less often than newer antidepressants because of their complex safety profile, including potentially serious interactions with certain foods, supplements, and medications. Classic oral MAOIs are associated with the risk of hypertensive crisis when combined with foods high in tyramine, and with serotonin syndrome or other adverse effects when combined with incompatible drugs. For this reason, MAOIs are often considered in more specialized settings, such as treatment-resistant depression, atypical depression, or selected anxiety-related conditions under close medical supervision.
Commonly discussed MAOIs include phenelzine, tranylcypromine, isocarboxazid, and the transdermal formulation of selegiline. Different MAOIs vary in how selectively they inhibit MAO-A or MAO-B and whether they act irreversibly or more selectively at lower doses. These pharmacologic differences can influence both clinical use and side-effect considerations. In addition to psychiatry, MAO inhibition also has relevance in neurology, especially because selective MAO-B inhibitors have been used in Parkinson’s disease.
From a broader health perspective, MAOIs occupy an important place in medicine because they illustrate the balance between high therapeutic potential and careful risk management. They remain clinically meaningful despite being older drugs, and research continues to examine where they may offer unique benefit. Any discussion of MAOIs also requires attention to medication reconciliation, dietary counseling, and coordination with qualified healthcare professionals, given the potentially serious consequences of interactions.
Western Medicine Perspective
Western Medicine Perspective
In conventional medicine, MAOIs are understood primarily through neuropharmacology. Monoamine oxidase exists in two major forms, MAO-A and MAO-B, both of which metabolize key monoamine neurotransmitters. Inhibiting these enzymes can increase central nervous system levels of serotonin, norepinephrine, and dopamine, pathways that are strongly implicated in depression and other neuropsychiatric conditions. Clinical research suggests that MAOIs can be particularly valuable in some cases of treatment-resistant depression, atypical depression, and certain anxiety syndromes, although their use is typically reserved for situations where other options have been ineffective or poorly tolerated.
A major feature of the western medical approach is risk stratification and interaction management. Oral nonselective irreversible MAOIs require careful avoidance of tyramine-rich foods and many interacting medications, including certain antidepressants, stimulants, decongestants, opioids, and serotonergic agents. Studies and prescribing guidelines emphasize washout periods when switching between MAOIs and other psychiatric drugs to reduce the risk of severe reactions. Clinicians also monitor for side effects such as orthostatic hypotension, insomnia, weight changes, sexual dysfunction, edema, and rare but serious hypertensive or serotonergic complications.
In evidence-based practice, MAOIs are not regarded as first-line antidepressants for most patients, largely because safer and easier-to-manage alternatives are available. However, this does not mean they are obsolete. Psychiatric literature continues to describe MAOIs as important options in selected populations, particularly when symptom patterns or prior treatment history suggest a potentially favorable response. In neurology, selective MAO-B inhibitors such as selegiline and rasagiline have also been studied and used in Parkinson’s disease, reflecting a different but related therapeutic role for MAO inhibition.
Conventional care also stresses that MAOIs require close medical supervision, detailed review of all prescriptions and over-the-counter products, and careful communication across care settings. Because interaction risk can extend to supplements and herbal products, western medicine generally frames MAOIs as medications that demand unusually high attention to safety systems, patient education, and provider coordination.
Eastern & Traditional Perspective
Eastern and Traditional Medicine Perspective
Traditional medical systems such as Traditional Chinese Medicine (TCM) and Ayurveda do not classify illness according to monoamine oxidase activity or antidepressant drug classes. Instead, they generally interpret symptoms like low mood, fatigue, agitation, insomnia, digestive change, or emotional stagnation through broader functional patterns. In TCM, depressive and anxiety-related presentations may be discussed in terms such as qi stagnation, Heart and Shen disturbance, Liver qi constraint, Phlegm accumulation, or deficiencies involving the Heart, Spleen, or Kidney systems, depending on the symptom constellation. In Ayurveda, comparable symptoms may be viewed through imbalances of doshas and disturbances affecting the mind-body relationship, digestion, sleep, and vitality.
From an eastern perspective, a medication such as an MAOI may be seen as a strong intervention that alters symptoms at a biochemical level, while traditional approaches often emphasize constitutional pattern assessment, lifestyle rhythms, diet, mind-body practices, and individualized herbal frameworks. Some naturopathic and integrative practitioners may discuss stress burden, autonomic imbalance, inflammation, or sleep disruption alongside conventional psychiatric diagnoses. However, these frameworks are not substitutes for the pharmacologic realities of MAOIs, especially because traditional herbs, fermented products, and supplements may still interact with these medications.
An important integrative consideration is safety around herb-drug and food-drug interactions. Certain herbal products traditionally used for mood, energy, or cognitive support may affect neurotransmitters, blood pressure, or stimulant pathways and therefore raise concern when combined with MAOIs. Likewise, some traditionally prepared or fermented foods may contain tyramine, which is highly relevant in the context of classic MAOI therapy. For this reason, integrative care models generally emphasize communication between patients, psychiatrists, pharmacists, and any complementary medicine practitioners involved.
Overall, eastern and traditional systems may contribute a holistic interpretive lens for the lived experience of depression or related symptoms, but MAOIs themselves are fundamentally understood through modern pharmacology. The most responsible integrative perspective acknowledges the value of traditional symptom frameworks while recognizing that MAOI use requires rigorous conventional safety oversight and discussion with qualified healthcare professionals.
Related Topics
SSRIs
SSRIs — a medication in the health ontology.
How They Relate
SSRIs & MAOIs
Selective serotonin reuptake inhibitors (SSRIs) and monoamine oxidase inhibitors (MAOIs) are antidepressant classes with distinct mechanisms, use patterns, and safety considerations. SSRIs—such as ...
Evidence & Sources
Supported by multiple clinical trials and systematic reviews
- American Psychiatric Association Practice Guideline for the Treatment of Patients With Major Depressive Disorder
- U.S. Food and Drug Administration prescribing information for phenelzine, tranylcypromine, isocarboxazid, and selegiline
- National Institute of Mental Health (NIMH)
- StatPearls: Monoamine Oxidase Inhibitors
- The Lancet Psychiatry
- Journal of Clinical Psychiatry
- CNS Drugs
- National Center for Complementary and Integrative Health (NCCIH)
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication regimen.